Georgia's Online Cancer Information Center

Find A Clinical Trial

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer

Status
Active
Cancer Type
Lung Cancer
Trial Phase
Phase I
Eligibility
18 - 80 Years, Male and Female
Study Type
Treatment
NCT ID
NCT04495894
Protocol IDs
WINSHIP4977-20 (primary)
NCI-2020-02709
Study Sponsor
Emory University Hospital/Winship Cancer Institute

Summary

This phase I trial studies the side effects of ketorolac before surgery in treating patients with stage I-II non-small cell lung cancer or stage III renal cell cancer. Surgical trauma increases the production of prostaglandins and thromboxanes, which have tumor-promoting and immunosuppressive activities and reduce the activity of natural killer cells, which impairs the ability of the immune system to keep cancer cells in check. However, if given just before tissue injury, non-steroidal anti-inflammatory drugs, such as ketorolac, may be able to block the production of prostaglandins/thromboxanes and boost the activity of natural killer cells, thereby decreasing the risk of cancer coming back.

Objectives

PRIMARY OBJECTIVE:
I. To test the safety of a single pre-incisional dose of 30 mg ketorolac in patients undergoing surgery for stage I/II non-small cell lung cancer (NSCLC) and stage III renal cell cancer (RCC), as these are the stages of cancer most likely to develop a recurrence while still noting a benefit from the ketorolac.

SECONDARY OBJECTIVE:
I. To evaluate blood and tissue samples pre- and post-operatively to assess the impact of ketorolac on key inflammatory biomarkers using a standard cytokine panel.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ketorolac intravenously (IV) prior to standard of care surgery.

ARM II: Patients undergo standard of care surgery.

After completion of study treatment, patients are followed up for 90 days and then at 1 and 2 years post surgery.

Eligibility

  1. Pathology-proven or suspected stage 1 or 2 NSCLC and stage 3 T3N0 RCC, that require surgical resection as the treatment of choice
  2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
  3. Ability to understand and the willingness to sign an informed written consent
  4. Age >= 18 years and =< 80 years

Treatment Sites in Georgia

Emory Clinic


1365 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

Emory University Hospital - Atlanta


1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

Emory University Hospital - Midtown


550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411
www.emoryhealthcare.org

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.